+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Inflammatory Bowel Disease (IBD) Market - Analysis By Disease Indication (Crohn's Disease, Ulcerative Colitis), Drug Class, Distribution Channel, By Region, By Country (2021 Edition): Market Insights, Covid-19 Pandemic, Competition and Forecast (2021-2026)

  • ID: 5319373
  • Report
  • April 2021
  • Region: Global
  • 260 Pages
  • Azoth Analytics

FEATURED COMPANIES

  • AbbVie Inc.
  • Celgene
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer

The Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020, has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression.


Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol consumption and cigarette smoking are likely to contribute towards the growth of the IBD market.


Additionally, rise in investments in building a robust pipeline for IBD, increase in lifestyle-related risk factors and growing popularity of prebiotic and probiotic foods are likely to boost the growth of the global market during the forecast period.


The North America region dominates the market. In North America, rising prevalence and incidence of IBD across the region is the major driving factor for the market. Moreover, an increasing number of cigarette-smokers in United States and significant funding in the IBD field in Canada is further estimated to boost the growth of the IBD market in the region.


The IBD market in North America has remained at the forefront in terms of growth opportunities as well as developments in the field of Crohn’s Disease over the years. The region is likely to continue to account for a significant piece of the revenue pie over the next few years as well, thanks to the presence of several pharmaceutical and biosciences companies and the presence of numerous leading players in the field of Crohn’s Disease. 


Additionally, increasing geriatric population base and prevalence of Ulcerative Colitis and Crohn’s disease and also well-developed healthcare expenditure coupled with increased per capita healthcare expenditure across regions would enhance the growth of the market during the forecast period.


Scope of the Report


  • The report analyses the market by value.
  • The report analyses the market by disease Indication (Crohn’s Disease, Ulcerative Colitis).
  • The report further assesses the the market by drug class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Others).
  • The report further assesses the the market by distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).
  • The market has been analysed by region (North America, Europe and Asia Pacific) and By Country (United States, Canada, Germany, France, Italy, Spain, United Kingdom, China, Japan, India).
  • The key insights of the report have been presented through the frameworks of Major Mergers & Acquisitions, Recent Industry Developments. Also, the attractiveness of the market has been presented By Region, By Disease Indication, By Drug Class and By Distribution Channel. Additionally, trends, drivers and challenges of the industry has been analysed in the report. 
  • The companies analysed in the report include Johnson & Johnson, AbbVie Inc., Takeda, Pfizer, Roche, Celgene, GlaxoSmithKline, Novartis, UCB and Eli Lilly & Company.
  • The report presents the analysis of the market for the historical period of 2016-2020 and the forecast period of 2021-2026.

Key Target Audience


  • Pharmaceutical Companies
  • Diagnostics Companies
  • Pharma R&D Organizations
  • Research and Consulting Firms
  • Government and Research Organisations

Countries Covered


  • Canada
  • China
  • France
  • Germany
  • India
  • Italy
  • Japan
  • Spain
  • United Kingdom
  • United States
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc.
  • Celgene
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer

1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary


2. Strategic Recommendations3. Global Inflammatory Bowel Disease Market: Product Outlook
4. Global Inflammatory Bowel Disease Market: An Analysis
4.1 Market Size, By Value, Year 2016-2026
4.2 COVID-19 Impact on Inflammatory Bowel Disease Market


5. Global Inflammatory Bowel Disease Market Segmentation By Disease Indication (By Value)
5.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Disease Indication
5.2 Crohn's Disease - Market Size and Forecast (2016-2026)
5.3 Ulcerative Colitis - Market Size and Forecast (2016-2026)


6. Global Inflammatory Bowel Disease Market Segmentation By Drug Class (By Value)
6.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Drug Class
6.2 TNF Inhibitors - Market Size and Forecast (2016-2026)
6.3 Aminosalicylates - Market Size and Forecast (2016-2026)
6.4 Integrin Antagonists - Market Size and Forecast (2016-2026)
6.5 Others - Market Size and Forecast (2016-2026)


7. Global Inflammatory Bowel Disease Market Segmentation By Distribution Channel (By Value)
7.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Distribution Channel
7.2 Hospital Pharmacies - Market Size and Forecast (2016-2026)
7.3 Retail Pharmacies - Market Size and Forecast (2016-2026)
7.4 Online Pharmacies - Market Size and Forecast (2016-2026)


8. Global Inflammatory Bowel Disease Market: Regional Analysis
8.1 Competitive Scenario of Global Inflammatory Bowel Disease Market: By Region


9. North America Inflammatory Bowel Disease Market: An Analysis (2016-2026)
9.1 North America Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
9.2 North America Inflammatory Bowel Disease Market - Prominent Companies
9.3 Market Segmentation By Disease Indication (Crohn's Disease and Ulcerative Colitis.)
9.4 Market Segmentation By Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists and Others.)
9.5 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.)
9.6 North America Inflammatory Bowel Disease Market: Country Analysis
9.7 Market Opportunity Chart of North America Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)
9.8 Competitive Scenario of North America - By Country
9.9 United States Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
9.10 United States Inflammatory Bowel Disease Market Leading Companies
9.11 United States Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.
9.12 Canada Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
9.13 Canada Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class and Distribution Channel.


10. Europe Inflammatory Bowel Disease Market: An Analysis (2016-2026)
10.1 Europe Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
10.2 Europe Inflammatory Bowel Disease Market - Prominent Companies
10.3 Market Segmentation By Disease Indication (Crohn's Disease, Ulcerative Colitis)
10.4 Market Segmentation By Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Others.)
10.5 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.)
10.6 Europe Inflammatory Bowel Disease Market: Country Analysis
10.7 Market Opportunity Chart of Europe Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)
10.8 Competitive Scenario of Europe - By Country
10.9 France Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
10.10 France Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.
10.11 Germany Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
10.12 Germany Inflammatory Bowel Disease Market Leading Companies
10.13 Germany Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.
10.14 Italy Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
10.15 Italy Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.
10.16 Spain Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
10.17 Spain Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.
10.18 United Kingdom Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
10.19 United Kingdom Inflammatory Bowel Disease Market - Segmentation By Disease Indication, Drug Class, Distribution Channel.


11. Asia Pacific Inflammatory Bowel Disease Market: An Analysis (2016-2026)
11.1 Asia Pacific Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
11.2 Asia Pacific Inflammatory Bowel Disease Market - Prominent Companies
11.3 Market Segmentation By Disease Indication (Crohn's Disease and Ulcerative Colitis.)
11.4 Market Segmentation By Drug Class (TNF Inhibitors, Aminosalicylates, Integrin Antagonists, Others.)
11.5 Market Segmentation By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.)
11.6 Asia Pacific Inflammatory Bowel Disease Market: Country Analysis
11.7 Market Opportunity Chart of Asia Pacific Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)
11.8 Competitive Scenario of Asia Pacific - By Country
11.9 China Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
11.10 China Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.
11.11 India Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
11.12 India Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.
11.13 Japan Inflammatory Bowel Disease Market: Size and Forecast (2016-2026), By Value
11.14 Japan Inflammatory Bowel Disease Market Leading Companies
11.15 Japan Inflammatory Bowel Disease Market Segmentation By Disease Indication, Drug Class, Distribution Channel.


12. Global Inflammatory Bowel Disease Market Dynamics
12.1 Global Inflammatory Bowel Disease Market Drivers
12.2 Global Inflammatory Bowel Disease Market Restraints
12.3 Global Inflammatory Bowel Disease Market Trends


13. Market Attractiveness and Strategic Analysis
13.1 Market Attractiveness
13.1.1 Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Disease Indication, By Value (Year-2026)
13.1.2 Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Drug Class, By Value (Year-2026)
13.1.3 Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Distribution Channel, By Value (Year-2026)
13.1.4 Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Region, By Value (Year-2026)
13.2 Strategic Analysis
13.2.1 Mergers and Acquisitions
13.2.2 Recent Industry Developments


14. Competitive Landscape
14.1 Market Share Analysis


15. Inflammatory Bowel Disease Pipeline Development
15.1 Emerging Therapies in Inflammatory Bowel Disease


16. Company Profiles (Business Description, Financial Analysis, Business Strategy)
16.1 Johnson & Johnson
16.2 AbbVie Inc.
16.3 Takeda
16.4 Pfizer
16.5 Roche
16.6 Celgene
16.7 GlaxoSmithKline
16.8 Novartis
16.9 UCB
16.10 Eli Lilly & Company


List of Figures
Figure 1: Global Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 2: Etrasimod Global Forecast in UC (Ulcerative Colitis), in USD Million
Figure 3: Etrasimod Global Forecast in CD (Crohn's Disease), in USD Million
Figure 4: Global Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 5: Prevalence of Rheumatoid Arthritis, in million, from 2014-2019
Figure 6: Select pharmaceutical companies by number of inflammatory bowel disease drugs in development
Figure 7: Top future inflammatory bowel disease drugs by expected 2022 revenue, (in million U.S. dollars)
Figure 8: Diagnosed Incident Cases of Ulcerative Colitis, in both male and female, in all ages, 2016 and 2026
Figure 9: Diagnosed Incident Cases of Crohn's Diseases, in both male and female, in all ages, 2019 and 2029
Figure 10: Global Inflammatory Bowel Disease Market - By Disease Indication, 2020, 2026
Figure 11: Global Inflammatory Bowel Disease Market - By Crohn's Disease, By Value (USD Million), 2016-2026
Figure 12: Global Inflammatory Bowel Disease Market - By Ulcerative Colitis, By Value (USD Million), 2016-2026
Figure 13: Global Inflammatory Bowel Disease Market - By Drug Class, 2020, 2026
Figure 14: Global Inflammatory Bowel Disease Market - By TNF Inhibitors, By Value (USD Million), 2016-2026
Figure 15: Global Inflammatory Bowel Disease Market - By Aminosalicylates, By Value (USD Million), 2016-2026
Figure 16: Global Inflammatory Bowel Disease Market - By Integrin Antagonists, By Value (USD Million), 2016-2026
Figure 17: Global Inflammatory Bowel Disease Market - By Others, By Value (USD Million), 2016-2026
Figure 18: Global Inflammatory Bowel Disease Market - By Distribution Channel, 2020, 2026
Figure 19: Global Inflammatory Bowel Disease Market - By Hospital Pharmacies, By Value (USD Million), 2016-2026
Figure 20: Global Inflammatory Bowel Disease Market - By Retail Pharmacies, By Value (USD Million), 2016-2026
Figure 21: Global Inflammatory Bowel Disease Market - By Online Pharmacies, By Value (USD Million), 2016-2026
Figure 22: Global Inflammatory Bowel Disease Market, By Region, 2020, 2026
Figure 23: North America Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 24: North America Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 25: North America Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 26: North America Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 27: North America Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 28: North America Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 29: North America Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016 2026
Figure 30: Market Opportunity Chart of North America Inflammatory Bowel Disease Market By Country, By Value, (Year-2026)
Figure 31: North America Inflammatory Bowel Disease Market, By Country, 2020, 2026
Figure 32: United States Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 33: United State Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 34: United State Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 35: Ulcerative Colitis diagnosed & treated patients (in K) in the US in 2020 & 2030
Figure 36: Crohn's Disease diagnosed & treated patients (in K) in the US in 2020 & 2030
Figure 37: % of U.S. inflammatory bowel disease (IBD) patients that experienced select symptoms associated with IBD, 2019
Figure 38: United State Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 39: United States Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 40: United States Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 41: United States Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 42: Canada Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 43: Healthcare Expenditure, as a percentage of GDP, Canada, 2019
Figure 44: Canada Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 45: Canada Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 46: Canada Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 47: Canada Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 48: Europe Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 49: Europe Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 50: Europe Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 51: Pharmaceutical market value in top ten European countries in 2018, (in million euros)
Figure 52: Europe Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 53: Europe Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 54: Europe Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 55: Europe Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 56: Market Opportunity Chart of Europe Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)
Figure 57: Europe Inflammatory Bowel Disease Market - By Country, 2020, 2026
Figure 58: France Inflammatory Bowel Disease Market Size - By Value, 2016-2026 (USD Million)
Figure 59: Total revenue of the French drug market from 2010 to 2019, in maker pre-tax price, (in million euros)
Figure 60: France Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 61: France Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 62: France Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 63: France Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 64: Germany Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 65: Germany Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 66: Germany Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 67: Germany Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 68: Germany Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 69: Germany Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 70: Italy Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 71: Public Health Expenditure, in Italy, 2015 - 2019, (Euro Million)
Figure 72: Number of Individuals with Chronic Disease, By Type, 2018, (1000 Individuals)
Figure 73: Annual growth rate of the pharmaceutical market in Italy from 2017 to 2022
Figure 74: Italy Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 75: Italy Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 76: Italy Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 77: Italy Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 78: Spain Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 79: Pharmaceutical Spending (USD Per Capita), in Spain, 2016 - 2019
Figure 80: Number of pharmacies in Spain from 2007 to 2019
Figure 81: Spain Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 82: Spain Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 83: Spain Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 84: United Kingdom Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 85: United Kingdom Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 86: United Kingdom Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 87: Value size of the digital health industry in the United Kingdom (UK) in 2014 and 2018, (in million GBP)
Figure 88: Market Share of Top Pharma Companies in United Kingdom, in 2018
Figure 89: United Kingdom Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 90: United Kingdom Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 91: United Kingdom Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 92: Asia Pacific Inflammatory Bowel Disease Market Size - By Value, 2016-2026 (USD Million)
Figure 93: Asia Pacific Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 94: Asia Pacific Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 95: Projected Pharmaceuticals Sales, in USD Billion, in selected Asia Pacific countries
Figure 96: Asia Pacific Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 97: Asia Pacific Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 98: Asia Pacific Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 99: Asia Pacific Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 100: Market Opportunity Chart of Asia Pacific Inflammatory Bowel Disease Market - By Country, By Value (Year-2026)
Figure 101: Asia Pacific Inflammatory Bowel Disease Market - By Country, 2020, 2026
Figure 102: China Inflammatory Bowel Disease Market Size - By Value, 2016-2026 (USD Million)
Figure 103: China Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 104: China Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 105: China Online Healthcare Market in RMB Billions
Figure 106: Market Size of Biotech in China, from 2010 - 2018, in RMB Billion
Figure 107: China Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 108: China Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 109: China Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 110: India Inflammatory Bowel Disease Market Size - By Value, 2016-2026 (USD Million)
Figure 111: India Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 112: India Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 113: India Healthcare Sector Revenue Share
Figure 114: Sale of India Pharma Companies in Dec 2019, (Rs Crore)
Figure 115: India Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 116: India Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 117: India Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 118: Japan Inflammatory Bowel Disease Market Size, By Value, 2016-2026 (USD Million)
Figure 119: Japan Current Healthcare Expenditure Per Capita, 2015-2018 (In Numbers)
Figure 120: Japan Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 121: Japan Inflammatory Bowel Disease Market - By Disease Indication, By Value (USD Million), 2016-2026
Figure 122: Japan Inflammatory Bowel Disease Market - By Drug Class, By Value (USD Million), 2016-2026
Figure 123: Japan Inflammatory Bowel Disease Market - By Distribution Channel, By Value (USD Million), 2016-2026
Figure 124: Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Disease Indication, By Value (Year 2026)
Figure 125: Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Drug Class, By Value (Year 2026)
Figure 126: Market Attractiveness Chart of Global Inflammatory Bowel Disease Market - By Distribution Channel, By Value (Year 2026)
Figure 127: Market Attractiveness Chart of Global Inflammatory Bowel Disease Market By Region, By Value, (Year-2026)
Figure 128: Global Inflammatory Bowel Disease company market share (%), 2020
Figure 129: Johnson & Johnson Annual Sales Revenue (USD Million), 2016-2020
Figure 130: Johnson & Johnson Annual Net Income/Loss (USD Million), 2016-2020
Figure 131: Johnson & Johnson Sales Revenue Split, By Business Segment (%), FY2020
Figure 132: Johnson & Johnson Sales Revenue Split, By Geography Segment (%), FY2020
Figure 133: AbbVie Inc. Annual Sales Revenue (USD Million), 2016-2020
Figure 134: AbbVie Inc. Annual Net Income/Loss (USD Million), 2016-2020
Figure 135: AbbVie Inc. Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 136: AbbVie Inc. Sales Revenue Split, By Geography Segment (USD Million), FY2020
Figure 137: Takeda Annual Sales Revenue (USD Million), 2015-2018
Figure 138: Takeda Annual Net Income/Loss (USD Million), 2015-2018
Figure 139: Takeda Sales Revenue Split, By Business Segment (USD Million), FY2018
Figure 140: Takeda Sales Revenue Split, By Geography Segment (%), FY2018
Figure 141: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 142: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 143: Pfizer Sales Revenue Split, By Geography Segment (USD Million), FY2020
Figure 144: Roche Annual Sales Revenue (USD Million), 2016-2020
Figure 145: Roche Annual Net Income/Loss (USD Million), 2016-2020
Figure 146: Roche Sales Revenue Split, By Business Segment (%), FY2020
Figure 147: Roche Sales Revenue Split, By Geography Segment (%), FY2020
Figure 148: Celgene Annual Sales Revenue (USD Million), 2014-2018
Figure 149: Celgene Annual Net Income/Loss (USD Million), 2014-2018
Figure 150: GlaxoSmithKline Annual Sales Revenue (USD Million), 2016-2020
Figure 151: GlaxoSmithKline Annual Net Income/Loss (USD Million), 2016-2020
Figure 152: GlaxoSmithKline Sales Revenue Split, By Business Segment (%), FY2020
Figure 153: GlaxoSmithKline Sales Revenue Split, By Geography Segment (%), FY2020
Figure 154: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 155: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 156: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 157: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 158: UCB Annual Sales Revenue (USD Million), 2016-2020
Figure 159: UCB Annual Net Income/Loss (USD Million), 2016-2020
Figure 160: UCB Sales Revenue Split, By Geography Segment (%), FY2020
Figure 161: Eli Lilly and Company Annual Sales Revenue (USD Million), 2016-2020
Figure 162: Eli Lilly and Company Annual Net Income/Loss (USD Million), 2016-2020
Figure 163: Eli Lilly and Company Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 164: Eli Lilly and Company Sales Revenue Split, By Geography Segment (%), FY2020


List of Tables
Table A: IBD Opportunity - Target Patient Population Sizes
Table B: Key IBD Drugs Revenue in USD Million in 2019 and 2018
Table C: Approved biologics/ novel orals in UC (Ulcerative Colitis)
Table D: Approved biologics/ novel orals in CD (Crohn's Disease)
Table E: Phase III IBD drugs In development
Table F: Prominent Inflammatory Bowel Disease Companies operating in North America
Table G: Market share for the 10 top-selling originator biologics in Canada, 2018
Table H: Prominent Inflammatory Bowel Disease Companies operating in Europe
Table I: Prominent Inflammatory Bowel Disease companies operating in Asia Pacific
Table J: Overview of key pipeline assets in development for UC (Ulcerative Colitis)
Table K: Overview of key pipeline assets in development for CD (Crohn's Disease)
Note: Product cover images may vary from those shown

Loading
LOADING...

  • AbbVie Inc.
  • Celgene
  • GlaxoSmithKline
  • Johnson & Johnson
  • Novartis
  • Pfizer
  • Roche
  • Takeda
  • UCB and Eli Lilly & Company
Note: Product cover images may vary from those shown

Loading
LOADING...